sentiment_stocks,
One other point that runs parallel to this is that the chart for NWBO IS predictive but has also been manipulated within it’s predictive nature. Those that know “the process” knew by 2017 that NWBO would provide a successful outcome having survived the 2015 attacks hence the first bottom. The first month after the true long term double bottom in 2020, as data lock was approaching, established an initial ~$.01 per month rise in price which even the attack on May 10th did not break through. That was no accident and it coincided with the last and lowest rate long term uptrend left on the chart. We see the manipulation within the chart when doubts created about plans for a journal article and a statement from the company about plans to seek approval were interrupted, possibly because the journal would not front run ECA guidance from FDA, and then supplanted with the need to put info out to the scientific community at NYAS beforehand in “the process“ to approval by presenting the need and methods for ECA usage at a scientific conference and this was then used to reinforce a lie that the trial failed because the original PFS had failed, the original bear claim as to the reason for the hold in 2015. On a side note, AVII77’s honesty in his discussion about failed PFS coupled with a good OS possibly being a good thing may be why we don’t see him here much any more dismissing approval possibilities. Very noticeable absence since before May 10th as his last post here was on 2-16-2022 #444569 ; ).
As to current price, the chart predicts that news will take the price to $11.50 or above relatively quickly then to a range up to over $25 as the uptrend shifts to the higher zone based on all the positives to come. This shift was anticipated to come earlier based on hopes for an earlier journal publication time but that seems tied into MAA acceptance at a minimum now. Best wishes.
AI
Market Data 
Markets 
